A Single-volunteer Study of Immune Response Following OTS-412 Vaccinia Virus Systemic Injection(Self-experiment)

Bionoxx Inc.

Status and phase: Completed; Early Phase 1

Conditions: Healthy Volunteer

Treatments: Biological: OTS-412

Study type: Interventional

Funder types: Industry

Identifiers

NCT07302945

OTS412-HV

Details and patient eligibility

About

Following oncolytic virus (OV) administration, the host immune response is initiated immediately and evolves dynamically. However, in clinical OV therapy, it is virtually impossible to capture these immune events in real time. To address this gap, the principal investigator conducted a high-resolution immune monitoring study in a healthy volunteer.

Enrollment: 1 patient

Sex: Male

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• A healthy adult

Exclusion criteria

• N/A

Trial design

Primary purpose: Basic Science

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

1 participants in 1 patient group

OV Treated healthy arm

Experimental group

Treatment:

Biological: OTS-412